COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 1183: Articles 11821-11830  | Next

Collateral positives of COVID-19 for culturally and linguistically diverse communities in Western Sydney, Australia
Cornell, S., Ayre, J., Mac, O. A., Kapoor, R., Pickles, K., Batcup, C., Dolan, H., Bonner, C., Cvejic, E., Mouwad, D., Zacharia, D., Tularic, U., Santalucia, Y., Chen, T., Vasic, G., McCaffery, K. J., Muscat, D. M.
10.1101/2021.10.20.21265299 — Posted: 2021-10-23
Epidemic Surveillance Models for Containing the Spread of SARS-CoV-2 Variants: Taiwan Experience
Yen, A. M.-F., Chen, T. H.-H., Chang, W.-J., Lin, T.-Y., Jen, G. H.-H., Hsu, C.-Y., Wang, S.-T., Dang, H., Chen, S. L.-S.
10.1101/2021.10.19.21265107 — Posted: 2021-10-23
In-person schooling and associated COVID-19 risk in the United States over Spring Semester 2021
Wiens, K. E., Smith, C. P., Badillo-Goicoechea, E., Grantz, K. H., Grabowski, M. K., Azman, A. S., Stuart, E. A., Lessler, J.
10.1101/2021.10.20.21265293 — Posted: 2021-10-23
Regional excess mortality during the 2020 COVID-19 pandemic: a study of five European countries
Konstantinoudis, G., Cameletti, M., Gomez-Rubio, V., Leon Gomez, I., Pirani, M., Baio, G., Larrauri, A., Riou, J., Egger, M., Vineis, P., Blangiardo, M.
10.1101/2021.10.18.21264686 — Posted: 2021-10-23
The Mask-Wearing Bias In The Estimates Of Vaccine Efficacy
Matytsin, A.
10.1101/2021.10.19.21265093 — Posted: 2021-10-23 Discussion: Onsite
Variations in cell-surface ACE2 levels alter direct binding of SARS-CoV-2 Spike protein and viral infectivity: Implications for measuring Spike protein interactions with animal ACE2 orthologs
Kazemi, S., Lopez-Munoz, A. D., Holly, J., Jin, L., Yewdell, J. W., Dolan, B. P.
10.1101/2021.10.21.465386 — Posted: 2021-10-23
Molecular Insights into the Differential Dynamics of SARS-CoV-2 Variants of Concern (VOCs)
Mandal, N., Padhi, A. K., Rath, S. L.
10.1101/2021.10.22.465272 — Posted: 2021-10-22
Underlying selection for the diversity of Spike protein sequences of SARS-CoV-2
Basak, S.
10.1101/2021.10.22.465411 — Posted: 2021-10-22
Gramicidin S and Melittin - Potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection
Enayathullah, M. G., Parekh, Y., Banu, S., Ram, S., Nagaraj, R., Kiran Kumar, B., Idris, M. M.
10.1101/2021.10.21.465254 — Posted: 2021-10-22
Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination
Zhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Deng, S., Tam, R. C.-Y., Huang, H., Zhang, A. J., Zhou, D., Zhou, B., Chan, C.-Y., Du, Z., Yang, D., Au, K.-K., Yuen, K.-Y., Chen, H., Chen, Z.
10.1101/2021.10.21.465252 — Posted: 2021-10-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).